Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)

Phase 1CompletedNCT00914121

Wyeth is now a wholly owned subsidiary of Pfizer60 enrolled

Overview

The purpose of this study is to examine the effect of SKI-606 on rhythms of the heart (cardiac repolarization)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy Subjects

Interventions

SKI-606DRUG

PlaceboDRUG

MoxifloxacinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Men or women of nonchildbearing potential; 18-50 years old; healthy as determined by the investigator, including physical examination, laboratory test results, and medical history.

Locations (1)

Unnamed facility

Tacoma, Washington, United States

Outcomes

Primary Outcomes

Corrected QT interval, including QTcN, QTcB, and QTcF

Time frame: 6 weeks

Secondary Outcomes

Laboratory evaluations, Vital Sign measurements, Adverse Event reports

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.